PharmaEssentia Corporation - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 28

PharmaEssentia Corporation – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “PharmaEssentia Corporation - Product Pipeline Review - 2012” provides data on the PharmaEssentia Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, PharmaEssentia Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from PharmaEssentia Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- PharmaEssentia Corporation - Brief PharmaEssentia Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PharmaEssentia Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of PharmaEssentia Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PharmaEssentia Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate PharmaEssentia Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PharmaEssentia Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PharmaEssentia Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PharmaEssentia Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PharmaEssentia Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of PharmaEssentia Corporation; PharmaEssentia Corporation - Key Therapeutics; PharmaEssentia Corporation - Pipeline Overview and Promising Molecules; PharmaEssentia Corporation - News; PharmaEssentia Corporation - Latest Updates; PharmaEssentia Corporation - Pipeline; PharmaEssentia Corporation - Discontinued/Dormant Projects

2
List of Tables 3
List of Figures 3
PharmaEssentia Corporation Snapshot 4
PharmaEssentia Corporation Overview 4
Key Information 4
Key Facts 4
PharmaEssentia Corporation – Research and Development Overview 5
Key Therapeutic Areas 5
PharmaEssentia Corporation – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
PharmaEssentia Corporation – Pipeline Products Glance 9
PharmaEssentia Corporation Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
PharmaEssentia Corporation – Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
PharmaEssentia Corporation – Drug Profiles 12
P1101 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
P1104 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
P1116 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
P1118 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
P1130 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PharmaEssentia Corporation – Pipeline Analysis 18
PharmaEssentia Corporation – Pipeline Products by Therapeutic Class 18
PharmaEssentia Corporation – Pipeline Products By Target 20
PharmaEssentia Corporation – Pipeline Products by Route of Administration 21
PharmaEssentia Corporation – Pipeline Products By Mechanism of Action 22
PharmaEssentia Corporation – Locations And Subsidiaries 23
Head Office 23
PharmaEssentia Corporation, Recent Developments 24
PharmaEssentia Corporation- Press Release 24
Dec 11, 2009: PharmaEssentia Announces Commencement Of Phase I Clinical Trial For Its HBV/HCV Drug Candidate P1101 (PEG-P-IFN-alpha) 24
Dec 08, 2009: PharmaEssentia Receives FDA Approval For Hepatitis Drug 24
Aug 04, 2009: PharmaEssentia's Long-acting HC/BV Drug Candidate P1101 (PEG-P-IFN-alpha-2b) Receives FDA IND Approval 25
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables
PharmaEssentia Corporation, Key Information 4
PharmaEssentia Corporation, Key Facts 4
PharmaEssentia Corporation – Pipeline by Indication, 2012 6
PharmaEssentia Corporation – Pipeline by Stage of Development, 2012 7
PharmaEssentia Corporation – Monotherapy Products in Pipeline, 2012 8
PharmaEssentia Corporation – Phase II, 2012 9
PharmaEssentia Corporation – Pre-Clinical, 2012 10
PharmaEssentia Corporation – Discovery, 2012 11
PharmaEssentia Corporation – Pipeline By Therapeutic Class, 2012 19
PharmaEssentia Corporation - Pipeline By Target, 2012 20
PharmaEssentia Corporation – Pipeline By Route of Administration, 2012 21
PharmaEssentia Corporation – Pipeline Products By Mechanism of Action, 2012 22

List of Figures
PharmaEssentia Corporation – Pipeline by Indication, 2012 6
PharmaEssentia Corporation – Pipeline by Stage of Development, 2012 7
PharmaEssentia Corporation – Monotherapy Products in Pipeline, 2012 8
PharmaEssentia Corporation – Pipeline By Therapeutic Class, 2012 18
PharmaEssentia Corporation - Pipeline By Target, 2012 20
PharmaEssentia Corporation - Pipeline Products By Mechanism of Action, 2012 22

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Altera Corporation
• Bose Corporation
• SYNNEX Corporation
• Avocent Corporation - SWOT Analysis
• Ixia - Company Analysis
• Black & Decker Corporation - SWOT Analysis
• SanDisk Corporation
• Nortel Networks Corporation